Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic Study of Erlotinib Toxicity in Advanced Solid Tumors
NCT00063895Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), ovarian cancer and squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Primary endpoint: Rate of diarrhea and skin rash across the short, medium, and long genotype frequencies of the CA polymorphism at Week 6. Started Apr 2003; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancersquamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00063895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063895.